Movement Alert｜Guardant Health Rises 5.87% in Pre-Market Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines

Market Focus05-28

On May 28, Guardant Health rose 5.87% in pre-market trading, trading at $127.78/share, with trading volume of $84,800.

On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.

This development comes shortly after another significant milestone for the company. On May 21, the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx liquid biopsy test as a companion diagnostic tool for multiple therapies in non-small cell lung cancer and colorectal cancer. That test integrates genomic and epigenomic analysis through a single blood draw, with genomic coverage expanded 100-fold compared to the previously approved version, delivering results within seven days.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1146659061?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-28 16:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1146659061","market":"us","top_or_hot":-1,"title":"Movement Alert｜Guardant Health Rises 5.87% in Pre-Market Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines","media":"Market Focus","content":"<p><p>On May 28, Guardant Health rose 5.87% in pre-market trading, trading at $127.78/share, with trading volume of $84,800.</p><p>On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.</p><p>This development comes shortly after another significant milestone for the company. On May 21, the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx liquid biopsy test as a companion diagnostic tool for multiple therapies in non-small cell lung cancer and colorectal cancer. That test integrates genomic and epigenomic analysis through a single blood draw, with genomic coverage expanded 100-fold compared to the previously approved version, delivering results within seven days.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Guardant Health Rises 5.87% in Pre-Market Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Guardant Health Rises 5.87% in Pre-Market Trading, Shield Blood Test Included in American Cancer Society Screening Guidelines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-05-28 16:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On May 28, Guardant Health rose 5.87% in pre-market trading, trading at $127.78/share, with trading volume of $84,800.</p><p>On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.</p><p>This development comes shortly after another significant milestone for the company. On May 21, the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx liquid biopsy test as a companion diagnostic tool for multiple therapies in non-small cell lung cancer and colorectal cancer. That test integrates genomic and epigenomic analysis through a single blood draw, with genomic coverage expanded 100-fold compared to the previously approved version, delivering results within seven days.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GH","symbol_name":"Guardant Health Inc.","start_time":0,"source_url":"","article_id":"1146659061","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1146659061","pubTimestamp":1779957334,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On May 28, Guardant Health rose 5.87% in pre-market trading, trading at $127.78/share, with trading volume of $84,800.On the news front, the company announced that its Shield blood test has been...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GH":"Guardant Health Inc."},"translate_title":"动静快讯|Guardant Health盘前涨5.87%盾验血纳入美国癌症协会筛查指南","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GH":1},"content_text":"On May 28, Guardant Health rose 5.87% in pre-market trading, trading at $127.78/share, with trading volume of $84,800.On the news front, the company announced that its Shield blood test has been included in the American Cancer Society's updated Colorectal Cancer Screening guidelines. The guidelines recommend Shield as an option for patients who decline or have not completed stool-based or visual examination screening tests for colorectal cancer, further validating the company's clinical value in the liquid biopsy space.This development comes shortly after another significant milestone for the company. On May 21, the U.S. Food and Drug Administration approved its Guardant360 Liquid CDx liquid biopsy test as a companion diagnostic tool for multiple therapies in non-small cell lung cancer and colorectal cancer. That test integrates genomic and epigenomic analysis through a single blood draw, with genomic coverage expanded 100-fold compared to the previously approved version, delivering results within seven days.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1146659061","isCrawlerRequest":true}